Skip to main content

Table 3 Adverse events (VCOG-CTCAE)

From: Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer

 

Grade

sDox

sDox + I2

mDox

mDox + I2

Vomiting

1

1 (25%)

1 (17%)

1 (17%)

2 (18%)

2

1 (25%)

1(17%)

1 (17%)

 

3

    

4

    

Diarrhea

1

1 (25%)

1 (17%)

1 (17%)

2 (18%)

2

1 (25%)

1 (17%)

1 (17%)

1 (9%)

3

    

4

    

Anorexia

1

2 (50%)

1 (17%)

1 (17%)

1 (9%)

2

1 (25%)

1 (17%)

  

3

    

4

    

Lethargy

1

1 (25%)

1 (17%)

1 (17%)

1 (9%)

2

1 (25%)

1 (17%)

1 (17%)

1 (9%)

3

    

4

    

Anemiaa

1

2 (50%)

2 (33%)

2 (33%)

3 (27%)

2

    

3

    

4

    

Neutropenia

1

1(25%)

1 (17%)

1 (17%)

1 (9%)

2

    

3

    

4

    
  1. aAnemia includes: hematocrit, hemoglobin and erythrocyte values (mean globular volume and mean hemoglobin concentration)